jens juul holst glp-1 of the Novo Nordisk Foundation Center for Basic Metabolic Research and the University of Copenhagen was awarded the 2025 Breakthrough Prize in Life Sciences for his discovery and Jens Juul Holst, 17th Frontiers
Description
Liu et al., 2017 )
Obesity is now very common among patients with Crohns disease, yet there is limited guidance on how newer metabolic medications, particularly GLP-1 receptor agonists affect Crohns-related outcomes, presenting author Nakul Ganju, MD, an internal medicine resident at Howard University Hospital in Washington, DC, told GI & Hepatology News
Layla also provides treatments like Lipotropic (MIC) + B12, NAD+, and Glutathione
At the same time, they put the brakes on NLRP3 inflammasome activation in microglia and get AMPK dependent mitochondrial biogenesis and autophagy going
This is a practical strategy for the first few weeks of treatment when solid food tolerance is at its lowest
D., Berger N
